Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

28
Want to buy a house? This is how long you’ll have to save

2018-07-13 cnbc
If homeownership is your American dream, here is a wake-up call. It could take more than six years to save up for a down payment. High rents and high home prices have hit affordability where it hurts, lengthening the amount of time most potential buyers will need to even think about financing a home.
FMCCO FMCCP FMCCM Z FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ ZG FMCC FMCCS FMCCT

13
Z / Zillow Group, Inc. Class C 8-K (Current Report)

2018-07-03 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Z

169
Zillow Group Prices Class C Shares & Notes Public Offering

2018-07-02 zacks
Zillow Group (ZG - Free Report) recently announced the pricing of its concurrent underwritten public offerings of approximately 5.702 million shares of Class C capital stock at $57 per share. The company also priced its $325 million in aggregate principal amount of its convertible senior notes due in 2023. The notes carry an interest rate of 1.5%, payable semi-annually.
ZG Z MU NTAP NVDA

1
Z / Zillow Group, Inc. Class C 424B5 (Prospectus)

2018-06-29 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225918 CALCULATION OF REGISTRATION FEE
Z

1
Z / Zillow Group, Inc. Class C 424B5 (Prospectus)

2018-06-29 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225918 CALCULATION OF REGISTRATION FEE
Z

1
Z / Zillow Group, Inc. Class C 8-K (Current Report)

2018-06-29 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Z

2
Z / Zillow Group, Inc. Class C FWP

2018-06-29 sec.gov
FWP Free Writing Prospectus Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplements each dated June 27, 2018 to the
Z

16
Zillow Group Prices Public Offerings of $325 million of Class C Capital Stock and $325 million of 1.50% Convertible Senior Notes due 2023

2018-06-29 globenewswire
SEATTLE, June 28, 2018 (GLOBE NEWSWIRE) -- Zillow Group, Inc. (NASDAQ:Z) (NASDAQ:ZG) announced today the pricing of concurrent underwritten public offerings of 5,701,754 shares of its Class C capital stock (the “Shares”) at a price to the public of $57 per share and $325 million aggregate principal amount of its 1.50% convertible senior notes due 2023 (the “Notes”). Zillow Group also granted the underwriters of the Shares offering (the “Shares Offering”) a 30-day option to purchase up to an additional 855,263 Shares and the underwriters of the Notes offering (the “Notes Offering”) a 30-day option to purchase up to an additional $48.
ZG Z BR

169
Zillow Group to Commence Public & Senior Notes Offerings

2018-06-28 zacks
Zillow Group (ZG - Free Report) recently announced its intention to raise funds through concurrent underwritten public offerings and convertible unsecured senior notes. In this regard, the company intends to offer concurrent public offering of $325 million of its Class C capital stock and $325 million in aggregate principal amount of its senior notes. The notes will mature in 2023.
ZG Z MU NTAP NVDA

16
Zillow Group Announces Proposed Public Offerings of $325 million of Class C Capital Stock and $325 million of Convertible Senior Notes

2018-06-27 globenewswire
SEATTLE, June 27, 2018 (GLOBE NEWSWIRE) -- Zillow Group, Inc. (NASDAQ:Z) (NASDAQ:ZG) announced today that it intends to commence concurrent underwritten public offerings of $325 million in shares of its Class C capital stock (the “Shares”) and $325 million aggregate principal amount of its convertible senior notes due 2023 (the “Notes”). Zillow Group also intends to grant the underwriters of the Shares offering (the “Shares Offering”) a 30-day option to purchase up to an additional $48.
ZG Z BR

1
Z / Zillow Group, Inc. Class C 424B5 (Prospectus)

2018-06-27 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225918 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as ame
Z

2
Z / Zillow Group, Inc. Class C 424B5 (Prospectus)

2018-06-27 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225918 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amende
Z

1
Z / Zillow Group, Inc. Class C S-3ASR

2018-06-27 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on June 27, 2018 Registration No. 333-
Z

49
Time to Take Profits in Zillow Stock

2018-06-20 investorplace
Zillow (NASDAQ:ZG, NASDAQ:Z) has had a strong start to 2018. ZG stock (the Class A shares, which are slightly cheaper than Class C shares) has gained 58% so far this year and touched an all-time high this week.
GS MTCH RDFN FB ZG Z LEN DHI WIX

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to Z / Zillow Group, Inc. Class C on message board site Silicon Investor.

CFZ E-Wiggle Workspace Your opinion please Legalization of Street Drugs
Clown-Free Zone... sorry, no clowns allowed CCB vs ZEN truth board
Anything graphite based, CCB, Zen and hopefully much more. Amazon.com, Inc. (AMZN)
Canu0027t Beat Amazon! Zenyatta Free Speech Board
The Zenyatta Information Board Zman Market Timing
CUSIP: 98954M101